Futuristic lab in Swaziland with scientists conducting HIV viral load testing using the Biocentric platform.

HIV Viral Load Testing: How a New Platform Can Improve Access in Swaziland

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"Discover how the Biocentric® open real-time PCR platform is making HIV viral load quantification more accessible and accurate in resource-limited settings like Swaziland."


In the global fight against HIV, monitoring viral load (VL) is crucial for effective treatment. As more people receive antiretroviral therapy (ART), the demand for VL testing has surged, especially in resource-limited settings (RLS). However, the existing commercial VL testing methods aren't always suitable for these environments. This creates a critical need for accessible and accurate VL testing solutions.

Swaziland, a country with one of the highest HIV prevalence rates in the world, has been actively expanding its VL monitoring programs. To address the challenges of scalability and accessibility, various VL platforms have been introduced, including the Biocentric platform. This system offers a promising alternative, but its effectiveness needs to be thoroughly evaluated under real-world conditions.

A recent study conducted in Swaziland has explored the suitability and diagnostic accuracy of the Biocentric® open real-time PCR platform for plasma-based HIV viral load quantification. The study aimed to determine if the Biocentric platform could provide a reliable solution for VL testing in resource-constrained settings, ultimately contributing to better patient care and program outcomes.

AI Search Multiple angles on this topic

From Viral Load Discovery to Program Scale-Up

Viral load tests changed how HIV drugs were developed and approved and how HIV was managed in clinical care; they also demonstrated that HIV steadily progresses after infection. In 2014, the World Health Organization published guidance for implementing and scaling up HIV viral load testing through planning, scale-up, and sustainability phases. Later work in a resource-limited country compared the Biocentric Generic Viral Load platform with Abbott using 84 samples, reporting different proportions of patients with suppressed viral load on the two platforms.

What is the Biocentric Platform and How Does It Work?

Futuristic lab in Swaziland with scientists conducting HIV viral load testing using the Biocentric platform.

The Biocentric platform is a multi-manufacturer open system designed for nucleic acid amplification and detection. It consists of:

A fully automated RNA and DNA extractor (Arrow). A real-time PCR system (FluoroCycler® 96). The system uses Generic HIV Charge Virale assay and test kits, developed by the French Agency for Research on AIDS and viral hepatitis (ANRS). The Biocentric assay received CE certification by a European Notified Body (British Standards Institution) and has been submitted for WHO pre-qualification of in vitro diagnostics.

  • Open automated RNA and DNA extractor (Arrow)
  • Real-time PCR system (FluoroCycler® 96)
  • Generic HIV Charge Virale assay and test kits, developed by the French Agency for Research on AIDS and viral hepatitis (ANRS)
AI Search Multiple angles on this topic

Recent Evidence from Eswatini

A study of the Biocentric open real-time PCR platform evaluated dried blood spot-based HIV viral load testing in Eswatini by examining testing completion, correlation, agreement, and diagnostic accuracy at the clinical threshold of 1000 copies/mL. Separately, a prospective cohort study of Treat-All implementation in Eswatini found a higher hazard of viral suppression under Treat-All, with an adjusted hazard ratio of 1.12 and a 95% confidence interval of 1.01 to 1.23. The same study reported comparable hazards of viral failure, with an adjusted hazard ratio of 0.89 for Treat-All and a 95% confidence interval of 0.53 to 1.49.

Field and Measurement Limitations

Evidence on the Biocentric platform identifies important limitations in field evaluation. In the plasma-based study, most viral-load samples were below the platform's detection limit, reducing the sample size available for correlation and Bland–Altman analyses, and discrepant results were not fully investigated because insufficient leftover plasma prevented retesting on both methods. The research also notes that not all commercially available viral-load testing methods have been evaluated under field conditions. A separate report concludes that dried blood spot quantification using a newly configured Biocentric method can nevertheless contribute to contextualized testing strategies, particularly in remote settings and populations with higher viral-failure rates.

Unlike closed systems, the Biocentric platform offers greater flexibility and adaptability, allowing labs to use different reagents and customize protocols. This can be particularly advantageous in resource-limited settings, where supply chain issues and cost considerations often dictate testing strategies.

The Future of HIV Monitoring in Resource-Limited Settings

The study highlights the potential of the Biocentric platform as a valuable tool for HIV viral load quantification in resource-limited settings. Its comparable accuracy to reference methods, coupled with its adaptability and potential for cost-effectiveness, makes it a promising option for expanding access to essential HIV monitoring services. By addressing the specific needs and challenges of these settings, innovative solutions like the Biocentric platform can contribute to improved patient outcomes and more effective HIV control efforts.

AI Search Multiple angles on this topic

A Growing but Variously Estimated Market

Commercial forecasts point to continued expansion of the HIV viral load testing market, although the estimates differ. Growth Market Reports values the market at USD 2.94 billion in 2024 and projects USD 5.05 billion by 2033, while MarketIntelo reports a value of USD 2.8 billion in 2025 and projects USD 4.4 billion by 2034. Related market coverage segments HIV diagnostics by products, test types including viral load and CD4 tests, technologies such as molecular diagnostics, and settings ranging from hospitals and laboratories to at-home use; another overview distinguishes rapid and self-tests, laboratory immunoassays, molecular viral-load platforms, and near-patient molecular systems.

What the paired results show

For quantifiable viral loads, the measurements moved closely together, while the small average difference in the Bland–Altman analysis indicates little overall directional bias between methods.[1] [2]

Where the plasma evaluation is weakest

  • Most samples fell below the platform’s detection limit, leaving fewer quantifiable results for correlation and agreement analyses.[1]
  • The sample panel did not represent broad HIV genetic diversity, limiting how far the findings can be generalized.[1]
  • The platform used manual procedures that depend on experienced staff and may be more vulnerable to operational errors.[1]
  • Discordant results could not be fully investigated because insufficient leftover plasma prevented retesting with both methods.[1]

What was actually tested in paired Swaziland plasma samples

Sample size364 paired plasma samples[2]
SettingTwo health facilities and laboratories in Swaziland[2]
DurationOctober 2016 to March 2017[2]
ComparisonNational reference method[2]
Effect sizeSensitivity 88.6% and specificity 98.3% at 3.0 log10 copies/mL[2]
Confidence intervalSensitivity 95% CI 78.7 to 94.9; specificity 95% CI 96.1 to 99.4[2]
p-valuep < 0.01[2]
Times cited3[2]

How this platform compares with related evidence

The study’s estimates were broadly in line with an earlier evaluation against the HIV Amplicor Monitor assay, which reported sensitivity of 100% and specificity of 90%.[1]

A separate report found good Biocentric performance in Cameroon, a setting described as having broad HIV genetic variability.[1]

Together, these comparisons support the platform’s relevance beyond this field evaluation, while the study notes that other commercial viral-load methods have not all been assessed under field conditions.[1] [2]

What remains unresolved about field use

  • Can laboratories maintain consistent classification when staff have different levels of hands-on experience?[1] [2]

Sources

  1. Field suitability and diagnostic accuracy of the Biocentric® open real-time PCR platform for plasma-based HIV viral load quantification in Swaziland (Europe PMC, 2018)
  2. Field suitability and diagnostic accuracy of the Biocentric® open real-time PCR platform for plasma-based HIV viral load quantification in Swaziland (Springer Science and Business Media LLC, 2018)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1186/s12879-018-3474-1, Alternate LINK

Title: Field Suitability And Diagnostic Accuracy Of The Biocentric® Open Real-Time Pcr Platform For Plasma-Based Hiv Viral Load Quantification In Swaziland

Subject: Infectious Diseases

Journal: BMC Infectious Diseases

Publisher: Springer Science and Business Media LLC

Authors: Bernhard Kerschberger, Qhubekani Mpala, Paola Andrea Díaz Uribe, Gugu Maphalala, Roberto De La Tour, Sydney Kalombola, Addis Bekele, Tiwonge Chawinga, Mukelo Mliba, Nombuso Ntshalintshali, Nomcebo Phugwayo, Serge Mathurin Kabore, Javier Goiri, Sindisiwe Dlamini, Iza Ciglenecki, Emmanuel Fajardo

Published: 2018-11-14

Everything You Need To Know

1

What is the Biocentric platform?

The Biocentric platform is a system designed for HIV viral load quantification, offering a flexible and adaptable solution. It includes the Arrow automated RNA and DNA extractor, the FluoroCycler 96 real-time PCR system, and utilizes the Generic HIV Charge Virale assay and test kits. Its open nature allows for the use of different reagents and customization, which is particularly beneficial in resource-limited settings like Swaziland.

2

Why is HIV viral load testing important?

HIV viral load testing is essential for managing HIV and monitoring the effectiveness of antiretroviral therapy (ART). By measuring the amount of HIV in a patient's blood, healthcare providers can assess how well treatment is working. Accurate and accessible VL testing is crucial because as more people receive ART, the demand for testing increases, especially in areas with limited resources where traditional methods may not be feasible.

3

What is the significance of the Biocentric platform?

The Biocentric platform is significant because it addresses the challenges of HIV viral load testing in resource-limited settings. Its open design allows for greater flexibility in using different reagents and adapting to local supply chain issues and cost constraints. The study conducted in Swaziland aimed to assess its diagnostic accuracy and suitability, highlighting its potential to provide reliable VL testing, ultimately contributing to better patient care.

4

What was the purpose of the study in Swaziland?

The study in Swaziland explored the effectiveness of the Biocentric platform for HIV viral load quantification. The study aimed to determine if the Biocentric platform could provide a reliable solution for VL testing in resource-constrained settings. The study demonstrated the platform's comparable accuracy and adaptability, suggesting its value in expanding access to essential HIV monitoring services in resource-limited settings, thereby improving patient outcomes and HIV control efforts.

5

What are the implications of using the Biocentric platform?

The implications of using the Biocentric platform are significant for HIV control efforts in resource-limited settings. By offering an accurate, adaptable, and potentially cost-effective method for HIV viral load quantification, the platform can improve patient outcomes. Access to VL testing is essential to the ability to provide treatment and monitor the effectiveness of that treatment, leading to better HIV control and management, particularly in regions like Swaziland, where such resources are often limited.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.